US Pharma MarketingNovartis, Vertex and Ipsen extend pharma
Novartis, Vertex, Ipsen and United Therapeutics kick off second-half M&A activity with up to $12.6B in new deals, extending a 45-deal run from 2026 Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Biopharma's M&A engine is revved up and shows no signs of cooling off.
Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $12.6 ...
Source: Endpoints News